Tax loss sellingIt is not surprising that old and stale shareholders are selling to establish a tax loss. However they might reconsider if they were to look at the Investor Presentation on Nanosphere’s website:
https://static1.squarespace.com/static/523888c8e4b0aa3edb480eda/t/59fa0e86c83025414860d440/1509559946015/Presentation_Deck_Corazonfinal_final2.pdf On Slide 20, the market cap of NSHS (now $75million) is compared with that of GW Pharma of $3billion, i.e. 40x that of NSHS.
On Slide 16, NSHS’s US Total Revenue (Low end estimate) is projected at $1.4million in the First Year and $8.9million in the Second Year. This can be compared with GW Pharma’s Total Revenue of $13.3 million in the Year to September 2016, which had been falling for several years. [NB. I have no idea of their revenue figure for the past year to September 2017.]
This suggests to me that either NSHS is undervalued or GW Pharma is overvalued.
It should also be noted that GW Pharma is the manufacturer of Sativex, which NSHS asserts (on Slide 20) is nearly 50% less effective than Nano’s product and takes more than 3x longer to achieve peak concentration than Nano’s product.
I am more than happy to keep my NSHS holding for the long term!
AndrewC2